Asosiy kontentga oʻtish
Maqola

More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma

Tomáš Jelı́nekDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech RepublicRenata BezděkováDepartment of Clinical Hematology, University Hospital Brno, Brno, Czech RepublicDavid ŽihalaDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech RepublicTereza ŠevčíkováDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech RepublicAnjana Anilkumar SitharaDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech RepublicLenka PospíšilováSabina Ševčı́kováBabak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech RepublicPetra PolackovaDepartment of Clinical Hematology, University Hospital Brno, Brno, Czech RepublicMartin ŠtorkDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Czech RepublicZdeňka KnechtováDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Czech RepublicOndrej VenglárDepartment of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech RepublicVeronika KapustováUniversity Hospital OstravaTereza PopkováUniversity Hospital OstravaLudmila MuroňováUniversity Hospital OstravaZuzana ChyraUniversity Hospital OstravaMatouš HrdinkaUniversity Hospital OstravaMichal ŠimíčekUniversity Hospital OstravaJuan‐José GarcésCentro de Investigación Biomédica en Red de CáncerNoemí PuigHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233, Salamanca, SpainMaría‐Teresa CedenaHospital 12 de Octubre, CIBER-ONC number CB16/12/00369, Madrid, SpainArtur JurczyszynPlasma Cell Dyscrasia Center, Department of Hematology, Jagiellonian University Medical College, Faculty of Medicine Cracow, PolandJorge J. CastilloDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MAMiroslav PenkaDepartment of Clinical Hematology, University Hospital Brno, Brno, Czech RepublicJakub Radocha4th Department of Internal Medicine—Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech RepublicMaría‐Victoria MateosHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233, Salamanca, SpainJesús F. San MiguelClinica Universidad de NavarraBruno PaivaCentro de Investigación Biomédica en Red de CáncerLuděk PourBabak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech RepublicLucie ŘíhováDepartment of Clinical Hematology, University Hospital Brno, Brno, Czech RepublicRoman HájekDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
2022en
ABI

Annotatsiya

PURPOSE: Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels. METHODS: We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM-CLARIDEX trial. The largest published real-world cohort of patients with primary PCL was used for comparison of survival. Finally, we challenged the current 5% threshold for primary PCL diagnosis. RESULTS: = .023) than patients with < 2%. The 2% cutoff proved to be applicable also in transplant-eligible patients with MM and was successfully validated on an independent cohort of patients from the GEM-CLARIDEX trial. Most importantly, patients with 2%-20% CTCs had comparable dismal outcomes with primary PCL. Moreover, after revealing a low mean difference between flow cytometric and morphologic evaluation of CTCs, we showed that patients with 2%-5% CTCs have similar outcomes as those with 5%-20% CTCs. CONCLUSION: Our study uncovers that ≥ 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba